Company intelligence / Profile preview

Syntekabio

Ownership: Private
Development stage: Preclinical

Overview

Syntekabio is an AI drug discovery platform company focused on generating preclinical to IND-enabling candidates rapidly across various disease areas. They enable partners to advance assets to clinical stages and hold PIPE/IPO status on the Korean exchange.

Therapeutic areas: OncologyRare DiseasesImmunologyNeurologyInfectious Diseases
Modalities: Small moleculeAntibody drug (Monoclonal antibody)Cell therapyNeoantigen-based therapyDrug repurposing (Small molecule)Biomarker discovery (enabling technology)Combination therapy (platform supports this)
Industry: Drug Discovery Services

Partnerships

Domestic/global pharma companies and biotech firmsAcademic institutionsGovernment research labsCROs such as Eurofins/BPSbio/Wuxi/SundiaCancer vaccine developers/hospitals/research institutes

Beyond the preview

Go deeper on Syntekabio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syntekabio.

Explore the full profile